Clinical Trial Update: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating cabozantinib in RET-positive non-small cell lung cancer is ongoing with an unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Bologna | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN